Skip to content
Open access

Matrix metalloprotease-9 modulates microglial/macrophage responses in murine brain demyelination.

Jul 2026 · Acta Neuropathologica Communications · 1 citation · ⚡ 1 influential
Medicine

TL;DR

Findings indicate that MMP-9 does not directly regulate demyelination and remyelination in the CPZ-induced demyelination model, but increases microglial abundance, highlighting its indirect role in CNS demyelination.

Abstract

Multiple sclerosis (MS) is a chronic autoimmune disorder, in which the immune system targets the protective myelin sheath surrounding axons in the brain, spinal cord and optic nerve, leading to demyelination and ultimately neurodegeneration. Promoting remyelination to delay or halt disease progression remains a major therapeutic challenge in MS research. Matrix metalloproteases (MMPs) have been implicated in the pathogenesis of MS. Elevated levels of MMP-9 have been detected in cerebrospinal fluid (CSF), serum and demyelinating lesions of MS patients, where MMP-9 contributes to myelin breakdown, epitope generation, and leukocyte infiltration. In the in vivo experimental autoimmune encephalomyelitis and lysophosphatidylcholine (LPC) murine MS models, Mmp9-/- mice exhibited delayed resolution of disease symptoms, suggesting a role for MMP-9 in remyelination. In this study, we investigated the role of MMP-9 in demyelination and remyelination, using two complementary models: LPC-induced demyelination in ex vivo brain slices and cuprizone (CPZ)-induced demyelination in vivo. In LPC-treated slices, MMP-9 deficiency impaired remyelination via microglia/macrophage-mediated mechanisms. Consistently, Mmp9-/- mice displayed increased numbers of activated microglia/macrophages in the corpus callosum following CPZ intoxication, with modest persistence during remyelination compared to WT mice. Naïve Mmp9-/- microglia/macrophages also showed enhanced myelin debris phagocytosis compared to WT cells. However, MMP-9 deficiency had minimal impact on demyelination or remyelination in the CPZ model. Proteomic analysis of CSF revealed differential expression of inflammatory mediators, including decreased levels of CCL2 and CXCL9, whereas CCL20 was increased in Mmp9-/- CPZ-treated mice. Collectively, these findings indicate that MMP-9 does not directly regulate demyelination and remyelination in the CPZ-induced demyelination model, but increases microglial abundance, highlighting its indirect role in CNS demyelination.

Read PDF

Similar papers

Open access Aug 2026

Microglia drive demyelination via multiple sclerosis antibodies and BTK signaling

Inhibition of Bruton’s tyrosine kinase (BTK) limited microglial transcriptional changes and prevented myelin loss following microglial envelopment and support BTK inhibition as a therapeutic strategy to prevent demyelination by modulating microglia behavior.

Lindsay A. Osso, Helena J. Barr, Michael E. Stockton et al. · 0 citations
Open access Sep 2026

Fibronectin inhibition restores myelination in endothelial TNFR2-dependent nonremitting experimental autoimmune encephalomyelitis.

Therapeutically, systemic fibronectin inhibition restored regeneration and clinical remission, as well as prevented OPC accumulation at lesions, providing strong preclinical evidence for fibronectin-targeting therapies in MS and other demyelinating disorders.

Aikaterini Nanou, Konstantinos Apostolou-Karampelis, V. Triantafyllidou et al. · 0 citations
Review Open access Sep 2026

Selected Cytokines and Matrix Metalloproteinases in Pathogenesis and Treatment of Multiple Sclerosis

Multiple sclerosis (MS) is a progressive autoimmune disease of the nervous system (NS). Axonal degeneration, demyelination, and inflammation are the main mechanisms leading to the development of this disorder. In the course of MS, parenchymal cells in the NS are activated to produce cytokines and cytokine-induced prote...

J. Mroczko, A. Romanowicz, M. Łukaszewicz-Zając et al. · 0 citations
Review Sep 2026

Targeting the α7-nicotinic acetylcholine receptor in multiple sclerosis: Implications for immunomodulation and neuroprotection.

By integrating immunomodulatory and neuroprotective actions, α7-nAChR targeting represents a mechanistically compelling strategy for comprehensive disease modification in MS, although clinical translation remains contingent upon overcoming significant pharmacological and biomarker-related challenges.

A. Al-Dhahi, Hayder M. Al-kuraishy, Ahmed A. Mohamed et al. · 0 citations
Open access Sep 2026

Intracellular complement factor H protects neurons during CNS inflammation

Using single-nucleus RNA-sequencing analysis of RGCs from donors with MS and control individuals, it is found that CFH expression was strongly correlated with intrinsic resilience to RGC degeneration and reveals a non-canonical intracellular function of CFH in neurons.

Christina Mayer, Marcel S. Woo, J. Sonner et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.